A baby girl who was close to dying from cancer has been rescued by a cell therapy envisioned as a “one size fits all” treatment that had never been tested in people, doctors reported on Thursday.
The development is significant because it indicates that cell therapies, which represent an exciting new front in the battle against cancer, might not have to be customized for each patient, saving time and money.
It also represents one of the first times that a novel “genome editing” technique has been used to treat someone. The therapy was developed by Cellectis, a French biotechnology company.
But it is hard to say much based on one patient. Also, the girl has been in remission for only a few months, too little time to say she has been cured, said Waseem Qasim, one of the doctors who treated her at the Great Ormond Street Hospital in London.
Still, the girl’s doctors “think it is a remarkable outcome,” because she had not been helped by conventional therapies, Dr. Qasim said in an interview.
Cancer doctors have been electrified by a new approach that involves genetically altering patients’ T cells, the soldiers of the immune system, so that they can better attack cancers.
Some patients with certain blood cancers have made remarkable recoveries. They include a girl who received a treatment developed at the University of Pennsylvania and now licensed to Novartis. Other companies pursuing this approach, often called CAR-T, including Juno Therapeutics and Kite Pharma, have achieved large stock market valuations.
But the first versions of their experimental therapies require extracting the T cells from the patient, shipping them to a manufacturing plant where they can be altered, then sending them back and putting them back into the patient, something that will be logistically challenging and costly for thousands of patients. Cellectis’s therapy is meant to work for any patient with a particular type of leukemia.
Cellectis’s American depositary receipts soared 18 percent on Thursday, while shares of Juno fell 7 percent and those of Kite dipped 2 percent.
Still the personalized treatments could reach the market in the next couple of years, long before Cellectis’s treatment, which will not even enter early-stage clinical trials until next year.
The case of the girl’s recovery will be presented to doctors next month at the annual meeting of the American Society of Hematology in Orlando, Fla. But abstracts for that conference were made public Thursday, and the hospital publicized the case.
The girl, Layla Richards of London, had acute lymphoblastic leukemia. Doctors tried the usual chemotherapy, a bone marrow transplant and a new type of biotech drug, but nothing worked. Layla did not have enough T cells to allow doctors to extract them and make a personalized therapy.
Her parents, Ashleigh Richards and Lisa Foley, were counseled to consider palliative care to keep her comfortable until she died, Dr. Qasim said. But the parents were not willing to do that.
In what might be a lucky coincidence, the hospital was already manufacturing Cellectis’s cells in preparation for clinical trials. “We had them in our freezers,” Dr. Qasim said. He is also a professor at University College London, which worked with Cellectis on the treatment.
So, with permission from her parents and Cellectis, Layla became the first person to receive the treatment, on what is sometimes called a compassionate use basis.
Read more: Cell Therapy Untested in Humans Saves a Baby With Cancer
The Latest on: Experimental therapies
[google_news title=”” keyword=”experimental therapies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Experimental therapies
- Under protest, FDA to convene advisory panel to review controversial cell therapy for ALSon March 27, 2023 at 4:01 am
The FDA will convene a meeting of independent advisers to review a personalized cell therapy for ALS that the agency has previously refused to consider.
- Joining medical clinical trials and receiving new treatments can be tough. Here’s how a CT hospital is changing that.on March 27, 2023 at 2:30 am
Patients with difficult-to-treat diseases can join clinical trials, the vital studies that test new medications, more easily now, according to Dr. Roy Herbst, deputy director of the Yale Cancer Center ...
- Experimental pill sees cancer vanish entirely in a third of acute leukaemia patientson March 26, 2023 at 3:30 am
Terminal leukaemia patients who were not responding to treatment now have hope for a cure, thanks to a new experimental pill called revumenib. This drug has completely eliminated cancer in a third of ...
- MD Anderson patient's cancerous brain tumor shrinks after using experimental helmet for 6 monthson March 24, 2023 at 5:31 pm
Last October, we first told you about a woman with a deadly brain tumor undergoing an experimental treatment. ABC13's Mayra Moreno checked in on her, and her results are astonishing.
- Wheelchair-bound kids with fatal genetic disorder protest seeking faster treatmenton March 24, 2023 at 7:50 am
Kids suffering from Duchenne Muscular Dystrophy (DMD), a fatal genetic disease, and parents gathered at Jantar Mantar to seek faster treatment.
- Missouri attorney general defends blocking gender treatments for children: 'We've got to reset'on March 23, 2023 at 1:00 am
Missouri Attorney General Andrew Bailey says his office's recent move to regulate clinics that offer gender transition procedures and drugs to minors is about safeguarding children from experimental ...
- Osteoarthritis: Experimental Drug May Help Reduce Inflammation and Symptoms, Early Study Findson March 22, 2023 at 7:26 am
New research in an animal study, found that an experimental drug compound, R805/CX-011, reduced inflammation in the joints affected by osteoarthritis, while still managing pain and stiffness.
- Effective treatment in rare but deadly form of canceron March 21, 2023 at 10:39 am
An advanced surgical therapy has proved considerably more efficacious than conventional treatments for patients with melanoma in the eye (uveal) that has spread to the liver, a University of ...
- AG issues emergency rule to halt 'experimental' gender-affirming treatment for minorson March 20, 2023 at 1:27 pm
The Secretary of State, who has to approve the rule, said it could go into effect in "about 10 days" and would be in place for 180 days.
- The Best New Ways to Live Healthier—and Longer—From Apps to Experimental Treatmentson March 19, 2023 at 8:00 am
As with any new frontier, plenty of wellness prospectors are panning for gold, offering everything from apps that recommend lifestyle changes to clinics whose bespoke treatments aim to help you ...
via Bing News